Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Site-specific expression of transferrin receptor by human colon cancer cells directly correlates with eradication by antitransferrin recombinant immunotoxin.

Shinohara H, Fan D, Ozawa S, Yano S, Van Arsdell M, Viner JL, Beers R, Pastan I, Fidler IJ.

Int J Oncol. 2000 Oct;17(4):643-51.

PMID:
10995873
2.

Recombinant antibody fragments and immunotoxin fusions for cancer therapy.

Brinkmann U.

In Vivo. 2000 Jan-Feb;14(1):21-7. Review.

PMID:
10757057
3.
4.
5.

[Host factors that changes the distribution of immunotoxin].

Yamaguchi T, Takahashi T, Yokota T, Kitamura K, Noguchi A, Doi M, Chimori Y, Honda M, Noguchi A, Otsuji E, et al.

Gan To Kagaku Ryoho. 1990 Mar;17(3 Pt 2):570-4. Review. Japanese.

PMID:
2138873
6.

Modulation of tumor cell response to chemotherapy by the organ environment.

Fidler IJ, Wilmanns C, Staroselsky A, Radinsky R, Dong Z, Fan D.

Cancer Metastasis Rev. 1994 Jun;13(2):209-22. Review.

PMID:
7923551
7.

Recombinant immunotoxins for treating cancer.

FitzGerald DJ, Kreitman R, Wilson W, Squires D, Pastan I.

Int J Med Microbiol. 2004 Apr;293(7-8):577-82. Review.

PMID:
15149034
8.

Cell-targeting fusion constructs containing recombinant gelonin.

Lyu MA, Cao YJ, Mohamedali KA, Rosenblum MG.

Methods Enzymol. 2012;502:167-214. doi: 10.1016/B978-0-12-416039-2.00008-2. Review.

PMID:
22208986
9.

Immunotoxins: selection of cell-surface antigens and their corresponding monoclonal antibodies.

Bjorn MJ, Villemez CL.

Cancer Treat Res. 1988;37:255-77. Review. No abstract available.

PMID:
2908629
10.

Molecular mechanisms for organ-specific colon carcinoma metastasis.

Radinsky R.

Eur J Cancer. 1995 Jul-Aug;31A(7-8):1091-5. Review.

PMID:
7576998
11.

Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis.

Reiter Y, Pastan I.

Trends Biotechnol. 1998 Dec;16(12):513-20. Review.

PMID:
9881483
12.

KS1/4-DAVLB, a monoclonal antibody-vinca alkaloid conjugate for site-directed therapy of epithelial malignancies.

Bumol TF, Baker AL, Andrews EL, DeHerdt SV, Briggs SL, Spearman ME, Apelgren LD.

Targeted Diagn Ther. 1988;1:55-79. Review. No abstract available.

PMID:
2979063
13.

Regulation of tumor cell growth at organ-specific metastases.

Radinsky R, Fidler IJ.

In Vivo. 1992 Jul-Aug;6(4):325-31. Review.

PMID:
1520835
14.

[Value of human colonic cancer models by surgical cecal implantation in nude mice].

Pocard M, Middleton S, Northover J, Poupon MF.

Ann Chir. 1999;53(3):227-32. Review. French.

PMID:
10339865
15.

Structure-function analysis of the human transferrin receptor: effects of anti-receptor monoclonal antibodies on tumor growth.

Trowbridge IS, Collawn J, Jing S, White S, Esekogwu V, Stangel M.

Curr Stud Hematol Blood Transfus. 1991;(58):139-47. Review. No abstract available.

PMID:
1954762
16.

Therapeutic potential of anti-HIV immunotoxins.

Pincus SH.

Antiviral Res. 1996 Dec;33(1):1-9. Review.

PMID:
8955848
17.

Monoclonal antibody-mediated targeting of alkylating agents for the treatment of cancer.

Smyth MJ, Pietersz GA, Farquhar I, McKenzie C.

Targeted Diagn Ther. 1988;1:123-56. Review. No abstract available.

PMID:
2979055
18.

Immunotoxin therapy: assessment by animal models.

Griffin TW, Morgan AC, Blythman HE.

Cancer Treat Res. 1988;37:433-55. Review. No abstract available.

PMID:
2908638
19.

The use of anthracycline-antibody complexes for specific antitumor activity.

Pietersz GA, Smyth MJ, Farquhar I, McKenzie C.

Targeted Diagn Ther. 1988;1:25-53. Review. No abstract available.

PMID:
2979059
20.

Immunotoxin therapy.

Hall WA.

Neurosurg Clin N Am. 1996 Jul;7(3):537-46. Review.

PMID:
8823781

Supplemental Content

Support Center